Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial
Yuankai Shi, Puyuan Xing, Guowu Wu, Hongbo Wu et autres
au, us, cn (code pays fourni par la source)
0 citations
Research Square